{"id":66202,"date":"2021-03-25T14:07:28","date_gmt":"2021-03-25T20:07:28","guid":{"rendered":"https:\/\/milesfortis.com\/?p=66202"},"modified":"2021-03-25T14:07:28","modified_gmt":"2021-03-25T20:07:28","slug":"66202","status":"publish","type":"post","link":"https:\/\/milesfortis.com\/?p=66202","title":{"rendered":""},"content":{"rendered":"<p><a href=\"https:\/\/www.dailymail.co.uk\/health\/article-9393693\/Regenerons-antibody-cocktail-cuts-risk-hospitalization-death-COVID-19-70.html\">Regeneron&#8217;s antibody cocktail that Trump hailed as &#8216;key&#8217; to his speedy recovery cuts risk of COVID hospitalization and death by 70%, trial data show<\/a><\/p>\n<ul class=\"mol-bullets-with-font\">\n<li class=\"class\"><strong>Regeneron&#8217;s cocktail, a mixture of two drugs,\u00a0imitates antibodies that the body generates when fighting the coronavirus in order to boost the immune system<\/strong><\/li>\n<li class=\"class\"><strong>The antibody treatment was authorized by the FDA to treat mild to moderate cases of COVID-19 in November<\/strong><\/li>\n<li class=\"class\"><strong>Half a group of 4,500 mild-to-moderate COVID-19 patients at high risk of severe illness were given one of two doses of the\u00a0drugs<\/strong><\/li>\n<li class=\"class\"><strong>Both doses were found to reduce the risk of hospitalization or death by about 70% compared to a placebo<\/strong><\/li>\n<li class=\"class\"><strong>Recovery time was also shortened, with symptoms only lasting about 10 days in the cocktail group in comparison with 14 days in the placebo group<\/strong><\/li>\n<\/ul>\n<p><!--more--><\/p>\n<div>\n<p class=\"mol-para-with-font\">Regeneron&#8217;s\u00a0<a id=\"mol-058fdf70-8bf7-11eb-b1d6-89675b012cd1\" href=\"https:\/\/www.dailymail.co.uk\/news\/coronavirus\/index.html\">coronavirus<\/a>\u00a0antibody cocktail is effective at treating mild to moderate cases of COVID-19, new late-stage trial results suggest.<\/p>\n<p class=\"mol-para-with-font\">The treatment is a mixture of drugs casirivimab and imdevimab, and was developed by the New York City-based company in partnership with pharmaceutical firm Roche.<\/p>\n<p class=\"mol-para-with-font\">Known as REGEN-COV, the cocktail imitates antibodies that the body generates when fighting the virus in order to boost the immune system.<\/p>\n<div class=\"minute-media\">\n<div id=\"mplayer-player-placeholder-4ec1a074-199d-4146-af67-851cafa82a0e\" class=\"monti-placeholder-mm-player\">\n<div id=\"mplayer-player-container-4ec1a074-199d-4146-af67-851cafa82a0e\">\n<div id=\"mplayer-mplayer-close-bar-placeholder-4ec1a074-199d-4146-af67-851cafa82a0e\"><\/div>\n<div id=\"mplayer-read-more-placeholder-4ec1a074-199d-4146-af67-851cafa82a0e\">\n<div>\n<div>\n<div>The cocktail was given to former President <a id=\"mol-05816080-8bf7-11eb-b1d6-89675b012cd1\" href=\"https:\/\/www.dailymail.co.uk\/news\/donald_trump\/index.html\">Donald Trump<\/a>\u00a0when he was infected with COVID-19 in October 2020, and which he hailed as &#8216;key&#8217; to his speedy recovery.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"mol-para-with-font\">In<a class=\"class\" href=\"https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody\" target=\"_blank\" rel=\"nofollow noreferrer noopener\">\u00a0trial data\u00a0<\/a>released on Tuesday, Regeneron said the combination reduced the risk of hospitalization and death by 70 percent compared to a placebo in non-hospitalized patients.<\/p>\n<div class=\"artSplitter mol-img-group\">\n<div class=\"mol-img\">\n<div class=\"image-wrap fff-pic\"><img loading=\"lazy\" decoding=\"async\" id=\"i-d1d9fa4d7d416b80\" class=\"blkBorder img-share b-loaded\" src=\"https:\/\/i.dailymail.co.uk\/1s\/2021\/03\/23\/16\/40840874-9393693-image-a-4_1616515826094.jpg\" alt=\"Both doses of Regeneron's antibody cocktail were found to reduce the risk of hospitalization or death by about 70% in mild-to-moderate COVID-19 patients compared to a placebo\" width=\"634\" height=\"469\" \/><\/p>\n<div class=\"overlay-icon mobile-gallery\">\n<div class=\"mobile-gallery-icon\"><\/div>\n<p>+5<\/p><\/div>\n<\/div>\n<div class=\"container-3zJLP vertical-2XJd5\">\n<ul class=\"linksHolder-3KBa2\">\n<li class=\"linkItem-2NXrW shareIcon-8A2dW\"><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p class=\"imageCaption\">Both doses of Regeneron&#8217;s antibody cocktail were found to reduce the risk of hospitalization or death by about 70% in mild-to-moderate COVID-19 patients compared to a placebo<\/p>\n<\/div>\n<div class=\"artSplitter mol-img-group\">\n<div class=\"mol-img\">\n<div class=\"image-wrap fff-pic\"><img loading=\"lazy\" decoding=\"async\" id=\"i-ea41f3838642129b\" class=\"blkBorder img-share b-loaded\" src=\"https:\/\/i.dailymail.co.uk\/1s\/2021\/03\/23\/16\/38508302-9393693-Regeneron_s_antibody_cocktail_pictured_in_the_manufacturing_proc-a-17_1616517221951.jpg\" alt=\"Regeneron's cocktail, a mixture of two drugs, imitates antibodies that the body generates when fighting the virus to boost the immune system. Pictured:\u00a0\u00a0An employee works in a lab at the Regeneron Pharmaceuticals Westchester campus in Tarrytown, New York, making the cocktail, September 2020\" width=\"632\" height=\"422\" \/><\/p>\n<div class=\"overlay-icon mobile-gallery\">\n<div class=\"mobile-gallery-icon\"><\/div>\n<\/div>\n<\/div>\n<div class=\"container-3zJLP vertical-2XJd5\">\n<p>Regeneron&#8217;s cocktail, a mixture of two drugs, imitates antibodies that the body generates when fighting the virus to boost the immune system. Pictured:\u00a0\u00a0An employee works in a lab at the Regeneron Pharmaceuticals Westchester campus in Tarrytown, New York, making the cocktail, September 2020<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"mol-para-with-font\">&#8216;This is a landmark moment in the fight against COVID-19,&#8217; said\u00a0trial investigator Dr Suraj Saggar, Chief of Infectious Disease at Holy Name Medical Center in Teaneck, New Jersey, in a statement.<\/p>\n<p class=\"mol-para-with-font\">&#8216;With so many people still getting infected&#8230;these data underscore the need to rapidly adopt REGEN-COV as standard-of-care to offer high-risk patients their best chance to reduce serious consequences like hospitalization or death.&#8217;<\/p>\n<p class=\"mol-para-with-font\">The U.S. Food and Drug Administration (FDA) approved the cocktail &#8211; which involves 1,200 milligrams (mg) of each drug &#8211; for emergency use in November.<\/p>\n<p class=\"mol-para-with-font\">However, the drugs have been chronically underused with the Department of Health and Human Services estimating in January that about 75 percent of doses purchased by the government were unused.<\/p>\n<p class=\"mol-para-with-font\">For the trial, researchers looked at 4,567 mild-to-moderate COVID-19 patients who were at high risk of developing severe illness.<\/p>\n<div>\n<div id=\"p-22\" class=\"related-carousel with-fb-or-tw health half\" data-track-module=\"am-related_carousel^related_carousel\" data-track-selector=\".rotator-panels a:not([class*=external])\" data-dm-rotator-rotate=\"false\" data-track-pos=\"static\" data-preferred-shared-network-enabled=\"\" data-dm-rotator-auto-init=\"\" data-dm-rotator-active-class=\"active\" data-dm-rotator-page-count=\"1.0\" data-dm-social-article-auto-init=\"\" data-dm-rotator-page-size=\"1\">\n<div class=\"rotator bdrcc\">\n<div class=\"rotator-title\"><\/div>\n<\/div>\n<div class=\"fb\">\n<div class=\"share\">A total of 1,355 patients were given the traditional amalgamation of 1,200 mg of casirivimab and 1,200 mg of imdevimab.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"mol-para-with-font\">A smaller group of 736 patients were given a smaller dose &#8211; 1,200 mg total, meaning the patients received 600 mg of each drug.<\/p>\n<p class=\"mol-para-with-font\">Only about one percent of patients given either dose developed COVID-19-related complications compared to about three percent in the placebo groups.<\/p>\n<p class=\"mol-para-with-font\">Both doses were found to reduce the risk of hospitalization or death with 70 percent in the smaller dose group and 71 percent in the larger dose group.<\/p>\n<p class=\"mol-para-with-font\">In addition, recovery time was shortened with symptoms only lasting about 10 days in the cocktail group in comparison with 14 days in the placebo group.<\/p>\n<p class=\"mol-para-with-font\">The results have yet to be published in a scientific journal and have not yet been reviewed by independent scientists.<\/p>\n<div class=\"artSplitter mol-img-group mol-hidden-caption\">\n<div class=\"mol-img\">\n<div class=\"image-wrap fff-pic\"><img loading=\"lazy\" decoding=\"async\" id=\"i-dfb585fbca58329c\" class=\"blkBorder img-share b-loaded\" src=\"https:\/\/i.dailymail.co.uk\/1s\/2021\/03\/23\/16\/40840480-9393693-image-a-1_1616515548105.jpg\" alt=\"\" width=\"634\" height=\"442\" \/><\/p>\n<div class=\"overlay-icon mobile-gallery\">\n<div class=\"mobile-gallery-icon\"><\/div>\n<\/div>\n<\/div>\n<div class=\"container-3zJLP vertical-2XJd5\">\n<p><img loading=\"lazy\" decoding=\"async\" id=\"i-5fad47af05cc72ad\" class=\"blkBorder img-share b-loaded\" src=\"https:\/\/i.dailymail.co.uk\/1s\/2021\/03\/23\/16\/40841666-9393693-image-a-12_1616516808129.jpg\" alt=\"\" width=\"634\" height=\"426\" \/><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"artSplitter mol-img-group mol-hidden-caption\">\n<div class=\"mol-img\">\n<div class=\"image-wrap fff-pic\"><\/div>\n<\/div>\n<\/div>\n<div class=\"moduleFull mol-video\">\n<div class=\"item\">\n<div id=\"v-3247754607491107424\" class=\"vjs-video-container vjs-fixed vjs-span-two-col health\">\n<div id=\"vjs_video_3\" class=\"video-js vjs-default-skin vjs-paused vjs-controls-enabled mol-fe-animated-preview mol-empty-playlist vjs-visually-ready vjs-user-inactive\" data-opts=\"{&quot;linkBaseURL&quot;:&quot;https:\/\/www.dailymail.co.uk\/health\/article-9393693\/Regenerons-antibody-cocktail-cuts-risk-hospitalization-death-COVID-19-70.html#v-3247754607491107424&quot;,&quot;isMobile&quot;:false,&quot;duration&quot;:345000,&quot;src&quot;:&quot;https:\/\/videos.dailymail.co.uk\/video\/mol\/2020\/10\/16\/3247754607491107424\/1024x576_MP4_3247754607491107424.mp4&quot;,&quot;source&quot;:&quot;Reuters&quot;,&quot;playerId&quot;:&quot;default&quot;,&quot;title&quot;:&quot;Donald Trump praises 'incredible' antibody treatment 'regeneron'&quot;,&quot;preload&quot;:&quot;none&quot;,&quot;initialVideo&quot;:true,&quot;thumbnail&quot;:&quot;https:\/\/i.dailymail.co.uk\/1s\/2020\/10\/16\/21\/34487872-0-image-a-28_1602881084747.jpg&quot;,&quot;poster&quot;:&quot;https:\/\/i.dailymail.co.uk\/1s\/2020\/10\/16\/21\/34487872-0-image-a-29_1602881086366.jpg&quot;,&quot;syndicationService&quot;:null,&quot;shortURL&quot;:&quot;https:\/\/mol.im\/a\/9393693#v-3247754607491107424&quot;,&quot;plugins&quot;:{&quot;social-share&quot;:{&quot;embedUrl&quot;:&quot;https:\/\/www.dailymail.co.uk\/embed\/video\/2271438.html&quot;},&quot;autoplay-next-video&quot;:{&quot;videos&quot;:&quot;https:\/\/www.dailymail.co.uk\/api\/player\/2271438\/related-videos.json&quot;,&quot;countdown_time&quot;:10},&quot;ads-setup&quot;:{&quot;videoAdServerUrl&quot;:&quot;https:\/\/pubads.g.doubleclick.net\/gampad\/ads?sz=[size]&amp;iu=%2F424397508%2Fdm.video%2Fdm_video_health&amp;ciu_szs=&amp;impl=s&amp;gdfp_req=1&amp;env=vp&amp;output=xml_vast3&amp;unviewed_position_start=1&amp;url=[referrer_url]&amp;correlator=[timestamp]&quot;,&quot;adsEnabled&quot;:true,&quot;adsCancelTimeout&quot;:15000,&quot;screen&quot;:{&quot;width&quot;:636,&quot;height&quot;:358}},&quot;sources&quot;:{&quot;url&quot;:&quot;https:\/\/www.dailymail.co.uk\/api\/player\/3247754607491107424\/video-sources.json&quot;},&quot;flyout&quot;:{&quot;viewportOffset&quot;:0.4,&quot;switchBack&quot;:true,&quot;forceFlyout&quot;:{&quot;active&quot;:true,&quot;muted&quot;:true,&quot;switchBack&quot;:false}},&quot;tracking&quot;:{&quot;channelShortName&quot;:&quot;news&quot;,&quot;sponsored&quot;:null,&quot;referenceId&quot;:2271438,&quot;trackingType&quot;:&quot;embedded&quot;},&quot;animated-preview&quot;:{&quot;data-hd-fps&quot;:7,&quot;displayName&quot;:null,&quot;data-hd-frame-count&quot;:70,&quot;frames&quot;:150,&quot;width&quot;:636,&quot;src&quot;:&quot;https:\/\/videos.dailymail.co.uk\/preview\/mol\/2020\/10\/16\/8792358379381308554\/636x382_JPG-SINGLE_8792358379381308554.jpg&quot;,&quot;fps&quot;:0,&quot;data-film&quot;:&quot;https:\/\/videos.dailymail.co.uk\/preview\/mol\/2020\/10\/16\/8792358379381308554\/308x174_JPG_8792358379381308554.jpg&quot;,&quot;data-fps&quot;:7,&quot;data-video&quot;:&quot;https:\/\/videos.dailymail.co.uk\/preview\/mol\/2020\/10\/16\/8792358379381308554\/636x382_MP4_8792358379381308554.mp4&quot;,&quot;data-hd-film&quot;:&quot;https:\/\/videos.dailymail.co.uk\/preview\/mol\/2020\/10\/16\/8792358379381308554\/636x382_JPG-HD_8792358379381308554.jpg&quot;,&quot;data-hd-frame-width&quot;:636,&quot;data-frame-height&quot;:172,&quot;data-frame-width&quot;:308,&quot;data-frame-count&quot;:70,&quot;height&quot;:356,&quot;data-hd-frame-height&quot;:356},&quot;related-videos&quot;:{&quot;videos&quot;:&quot;https:\/\/www.dailymail.co.uk\/api\/player\/2271438\/related-videos.json&quot;}},&quot;videoId&quot;:&quot;3247754607491107424&quot;,&quot;descr&quot;:&quot;Donald Trump praised the 'incredible' coronavirus antibody treatment that he received. The treatment was developed by  Regeneron Pharmaceuticals.&quot;,&quot;referenceId&quot;:2271438,&quot;grapeshot&quot;:{&quot;article&quot;:{&quot;articleURL&quot;:&quot;https:\/\/www.dailymail.co.uk\/health\/article-9393693\/Regenerons-antibody-cocktail-cuts-risk-hospitalization-death-COVID-19-70.html&quot;}}}\">\n<div class=\"vjs-title\"><\/div>\n<div class=\"vjs-control-bar\">\n<div class=\"vjs-video-quality-control vjs-control\" tabindex=\"0\" role=\"button\" aria-live=\"polite\" aria-haspopup=\"true\">\n<div class=\"vjs-control-content\">\n<div class=\"vjs-menu\">\n<div class=\"vjs-menu-content\">\n<div class=\"vjs-menu-item\" tabindex=\"0\" role=\"button\" aria-live=\"polite\" aria-selected=\"false\">Regeneron says it plans to apply for FDA authorization for the lower dose of its antibody cocktail.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"mol-para-with-font\">&#8216;With approximately 60,000 newly diagnosed individuals in the U.S. every day and 40,000 still in the hospital because of COVID-19, we are committed to working with the government, health care providers and others to support rapid and widespread adoption of REGEN-COV in appropriate patients,&#8217; said Dr George Yancopoulos, Regeneron&#8217;s president and chief scientific officer, in a statement.<\/p>\n<p class=\"mol-para-with-font\">&#8216;We will rapidly discuss the new data with regulatory authorities and request that the 1,200 mg dose be added to the U.S. Emergency Use Authorization, in order for the anticipated REGEN-COV supply to be available to treat even more patients.&#8217;<\/p>\n<p class=\"mol-para-with-font\">Regeneron&#8217;s partner, Roche, is making the drug at its plants in California and is responsible for sales outside the U.S.<\/p>\n<p class=\"mol-para-with-font\">The two companies have stated that they believe they can produce more than two million doses of the cocktail annually.<\/p>\n<div class=\"artSplitter mol-img-group mol-hidden-caption\">\n<div class=\"mol-img\">\n<div class=\"image-wrap fff-pic\"><img loading=\"lazy\" decoding=\"async\" id=\"i-b07a87965a329a87\" class=\"blkBorder img-share b-loaded\" src=\"https:\/\/i.dailymail.co.uk\/1s\/2021\/03\/23\/16\/40840484-9393693-image-a-2_1616515574241.jpg\" alt=\"\" width=\"634\" height=\"433\" \/><\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron&#8217;s antibody cocktail that Trump hailed as &#8216;key&#8217; to his speedy recovery cuts risk of COVID hospitalization and death by 70%, trial data show Regeneron&#8217;s cocktail, a mixture of two drugs,\u00a0imitates antibodies that the body generates when fighting the coronavirus in order to boost the immune system The antibody treatment was authorized by the FDA &hellip; <a href=\"https:\/\/milesfortis.com\/?p=66202\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-66202","post","type-post","status-publish","format-standard","hentry","category-health-medicine"],"_links":{"self":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/66202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66202"}],"version-history":[{"count":1,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/66202\/revisions"}],"predecessor-version":[{"id":66203,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/66202\/revisions\/66203"}],"wp:attachment":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}